» Articles » PMID: 21416100

Topographic Enhancement Mapping of the Cancer-associated Breast Stroma Using Breast MRI

Overview
Specialty Biology
Date 2011 Mar 19
PMID 21416100
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In animal and laboratory models, cancer-associated stroma, or elements of the supporting tissue surrounding a primary tumor, has been shown to be necessary for tumor evolution and progression. However, little is understood or studied regarding the properties of intact stroma in human cancer in vivo. In addition, for breast cancer patients, the optimal volume of local tissue to treat surrounding a primary tumor is not clear. Here, we performed an interdisciplinary study of normal-appearing breast tissue using breast magnetic resonance imaging (MRI), correlative histology and array comparative genomic hybridization to identify a cancer-associated stroma in humans. Using a novel technique for segmenting breast fibroglandular tissue, quantifiable topographic percent enhancement mapping of the stroma surrounding invasive breast cancer was found to be significantly elevated within 2 cm of the tumor edge. This region was also found to harbor increased microvessel density, and genomic changes that were closely associated with host normal breast tissue. These findings indicate that a cancer-associated stroma may be identified and characterized in human breast cancer using non-invasive imaging techniques. Identification of a cancer-associated stroma may be further developed to help guide local therapy to reduce recurrence and morbidity in breast cancer patients.

Citing Articles

The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy.

Virostko J, Kuketz G, Higgins E, Wu C, Sorace A, DiCarlo J Eur J Radiol. 2021; 136:109534.

PMID: 33454460 PMC: 7897312. DOI: 10.1016/j.ejrad.2021.109534.


Prognostic Significance of CT-Attenuation of Tumor-Adjacent Breast Adipose Tissue in Breast Cancer Patients with Surgical Resection.

Lee J, Kim S, Lee H, Han S, Lee J, Lee S Cancers (Basel). 2019; 11(8).

PMID: 31398863 PMC: 6721593. DOI: 10.3390/cancers11081135.


Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.

Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M JAMA Netw Open. 2019; 2(4):e192561.

PMID: 31002322 PMC: 6481453. DOI: 10.1001/jamanetworkopen.2019.2561.


Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Olshen A, Wolf D, Jones E, Newitt D, J van t Veer L, Yau C J Med Imaging (Bellingham). 2018; 5(1):011014.

PMID: 29296631 PMC: 5741993. DOI: 10.1117/1.JMI.5.1.011014.


Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.

Wu J, Li B, Sun X, Cao G, Rubin D, Napel S Radiology. 2017; 285(2):401-413.

PMID: 28708462 PMC: 5673053. DOI: 10.1148/radiol.2017162823.


References
1.
Eng C, Leone G, Orloff M, Ostrowski M . Genomic alterations in tumor stroma. Cancer Res. 2009; 69(17):6759-64. DOI: 10.1158/0008-5472.CAN-09-0985. View

2.
Guidi A, Schnitt S, Fischer L, Tognazzi K, Harris J, Dvorak H . Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer. 1997; 80(10):1945-53. DOI: 10.1002/(sici)1097-0142(19971115)80:10<1945::aid-cncr11>3.0.co;2-y. View

3.
Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter G . Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007; 357(25):2543-51. DOI: 10.1056/NEJMoa071825. View

4.
Brown L, Guidi A, Schnitt S, Van de Water L, Iruela-Arispe M, Yeo T . Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res. 1999; 5(5):1041-56. View

5.
Campbell I, Polyak K, Haviv I . Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res. 2009; 69(17):6765-8. DOI: 10.1158/0008-5472.CAN-08-4253. View